Prognostic variables for patients with stage III malignant melanoma

被引:0
|
作者
Messaris, EG
Konstadoulakis, MM
Ricaniadis, N
Leandros, E
Androulakis, G
Karakousis, CP
机构
[1] Hippokrateio Hosp, Surg Res Lab, Propaedeut Surg Clin A, Athens, Greece
[2] Roswell Pk Canc Inst, Dept Surg Oncol, Buffalo, NY 14263 USA
关键词
malignant melanoma; stage III; prognostic factors;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To evaluate the prognostic factors for patients with stage III malignant melanoma and to identify patients at high risk of developing recurrent disease who may benefit from adjuvant therapy. Design: Retrospective study. Setting: Specialist hospital, USA. Subjects: 130 patients with stage III malignant melanoma (according to the TNM classification), treated at the Roswell Park Cancer Institute between 1970 and 1992. Main outcome measures: Survival and prognostic factors on multivariate analysis. Results: Four factors were independent prognostic indicators for patients with stage III malignant melanoma: age >51 years (p = 0.008), >3 involved lymph nodes, (p = 0.03), the site of the primary tumour on head or trunk, (p = 0.007), and the presence of palpable lymph nodes (p = 0.004). Conclusion: These prognostic factors help us to stratify patients into low and high-risk groups. High-risk patients may benefit from more aggressive adjuvant therapy in future trials of treatment of melanoma.
引用
收藏
页码:233 / 239
页数:7
相关论文
共 50 条
  • [21] Adjuvant therapies in the treatment of stage II and III malignant melanoma
    Kavanagh, D
    Hill, ADK
    Djikstra, B
    Kennelly, R
    McDermott, EMW
    O'Higgins, NJ
    SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND, 2005, 3 (04): : 245 - 256
  • [22] Adjuvant Therapeutic Decisions in Patients with Stage IIB/C and Stage III malignant Melanoma in everyday Clinical Practice
    Mechow, N.
    Peitsch, W. K.
    Diehl, K.
    Ohletz, J.
    Herz, J.
    Eisert, L.
    Harth, W.
    Weilandt, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024, 22 : 24 - 24
  • [23] The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma
    Weber, J. S.
    Hersh, E. M.
    Yellin, M.
    Nichol, G. M.
    Urba, W.
    Powderly, J. D.
    O'Day, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] IMMUNOLOGICAL PROGNOSTIC VARIABLES IN STAGE II MALIGNANT-MELANOMA - RELATIONSHIP TO SURVIVAL AND DISEASE-FREE INTERVAL (DFI)
    BUKOWSKI, RM
    HEWLETT, JS
    GREENSTREET, R
    DEODHAR, SH
    CLINICAL RESEARCH, 1979, 27 (02): : A382 - A382
  • [25] Prognostic biomarkers in stage II-III melanoma.
    Rizk, Emanuelle M.
    Gartrell, Robyn D.
    Chen, Andrew
    Chang, Rui
    Marks, Douglas K.
    Esancy, Camden L.
    Taback, Bret
    Horst, Basil A.
    Drake, Charles G.
    Rabadan, Raul
    Saenger, Yvonne M.
    CANCER RESEARCH, 2020, 80 (19) : 49 - 50
  • [26] Positron emission tomography scanning in malignant melanoma -: Clinical utility in patients with Stage III disease
    Tyler, DS
    Onaitis, M
    Kherani, A
    Hata, A
    Nicholson, E
    Keogan, M
    Fisher, S
    Coleman, E
    Seigler, HF
    CANCER, 2000, 89 (05) : 1019 - 1025
  • [27] THE ROLE OF BONE SCANS IN ASSESSING MALIGNANT-MELANOMA IN PATIENTS WITH STAGE-III DISEASE
    DEVEREUX, D
    JOHNSTON, G
    BLEI, L
    HEAD, G
    MAKUCH, R
    BURT, M
    SURGERY GYNECOLOGY & OBSTETRICS, 1980, 151 (01): : 45 - 48
  • [28] Prognostic Variables Associated with Improved Outcomes in Stage III NSCLC Patients Treated with Consolidation Pembrolizumab
    Anouti, B.
    Althouse, S.
    Durm, G.
    Breen, T.
    Hanna, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S627 - S627
  • [29] Circulating melanoma cells and recurrence in stage III melanoma patients
    Lucci, Anthony
    Hall, Carolyn S.
    Karhade, Mandar
    Laubacher, Barbara A.
    Bauldry, Jessica Bowman
    Royal, Richard Eldon
    Upshaw, Joshua
    Roland, Christina Lynn
    Ross, Merrick I.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Identification of markers prognostic of survival in lymph node metastases from stage III melanoma patients
    Mactier, S.
    Kaufman, K. L.
    Wang, P.
    Crossett, B.
    Yang, E.
    Scolyer, R. A.
    Yang, J.
    Mann, G. J.
    Christopherson, R. I.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S874 - S874